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INTRODUCTION
Ovarian cancer is one of the five most common can-
cers in women and it was the fifth most common
cause of death in women with cancer.1 In USA,
2009, there were 21,550 new cases of ovarian ma-
lignancy, with 14,600 deaths per year. Ovarian ma-
lignancy most commonly found in women aged 65
- 74 years old (25.3%).2,3
Abstract
Objective: To assess the effect of Paclitaxel-Carboplatin combina-
tion on epithelial ovarian cancer by studying the changes in VEGF se-
rum levels after receiving 3 series of chemotherapy.
Methods: This was a cohort study conducted at several teaching
hospitals in Obstetrics and Gynecology Department of the Faculty of
Medicine, Hasanuddin University from April 2011 to March 2012.
The subjects were patients with ovarian cancer who met the inclu-
sion criteria and had undergone surgery. The clinical staging was de-
termined with 2009 FIGO criteria. They went through histopathol-
ogy examination to determine the histological type and cell differen-
tiation of the lesion. They also went through combined chemother-
apy of Paclitaxel and Carboplatin. The data were analyzed with
paired t-test.
Results: The study reveals that out of 30 cases of ovarian cancer
who received a combination chemotherapy, most were < 45 years of
age (53.33%), nulliparous (46.7%), serosum type (53.3%), with
moderate differentiation (36.7%), and in advanced stage (73.3%).
The VEGF serum level after 3 series of chemotherapy was lower
than before (the average value: 294.67 vs 572.77 ng/ml). There was
a significant change in VEGF serum level after receiving chemother-
apy (p=0.000). The VEGF serum level of advanced-stage and early
stage epithelial ovarian cancer after chemotherapy decreases signifi-
cantly (p=0.000 and p=0.011). The advanced-stage cases showed
more responses to chemotherapy than the early-stage did. There
was a tendency that adenocarcinoma serosum type was more re-
sponsive to the therapy than mucinosum type (p=0.000 vs 0.003).
Conclusion: There is no difference in VEGF serum level based on cell
differentiation but there is a tendency that well and moderate differ-
entiated cells have a greater change than the poor differentiated cells
(p=0.003, p=0.003 vs p=0.019).
[Indones J Obstet Gynecol 2012; 36-3: 135-9]
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Abstrak
Tujuan: Penelitian ini bertujuan menilai respons kemoterapi kombi-
nasi paclitaxel - carboplatin pada kanker ovarium epitelial dengan
melihat perubahan kadar VEGF serum sesudah menjalani kemoterapi
3 seri.
Metode: Penelitian ini dilakukan pada periode April 2011 sampai
Maret 2012 di beberapa rumah sakit pendidikan Bagian Obstetri dan
Ginekologi Fakultas Kedokteran Universitas Hasanuddin. Jenis peneli-
tian ini adalah kohort. Subjek penelitian adalah penderita kanker
ovarium yang memenuhi kriteria inklusi dan telah menjalani operasi,
penentuan stadium klinis dengan kriteria FIGO 2009, pemeriksaan pa-
tologi anatomi yang dilakukan untuk menentukan tipe histologi, dife-
rensiasi sel, dan menjalani kemoterapi kombinasi paclitaxel - car-
boplatin. Data dianalisis dengan uji t berpasangan (Paired t-test).
Hasil: Hasil penelitian menunjukkan bahwa terdapat 30 kasus kanker
ovarium yang menjalani kemoterapi kombinasi paclitaxel-carboplatin
dengan kasus terbanyak pada usia kurang dari 45 tahun (53,33%),
nulliparitas (46,7%), tipe histologi serosum (53,3%), diferensiasi se-
dang (36,7%), dan stadium lanjut (73,3%). Kadar VEGF serum se-
sudah menjalani kemoterapi 3 seri lebih rendah daripada sebelum
menjalani kemoterapi (294,67 vs 572,77 ng/ml, mean). Terdapat per-
bedaan yang signifikan antara kadar VEGF serum sebelum dan se-
sudah menjalani kemoterapi (p=0,000). Kadar VEGF serum kanker
ovarium epitelial stadium lanjut dan stadium awal secara signifikan
mengalami penurunan setelah kemoterapi (p=0,000 dan p=0,011), na-
mun stadium lanjut menunjukkan hasil yang lebih responsif terhadap
kemoterapi dibandingkan dengan stadium awal. Terdapat kecen-
derungan pada tipe adenokarsinoma serosum lebih responsif ter-
hadap kemoterapi dibandingkan dengan tipe musinosum (p=0,000 vs
0,003).
Kesimpulan: Tidak ada perbedaan yang signifikan kadar VEGF se-
rum berdasarkan diferensiasi sel, namun ada kecenderungan diferen-
siasi baik dan sedang mengalami perubahan lebih besar diband-
ingkan diferensiasi jelek (p=0,003,p=0,003 vs p=0,019).
[Maj Obstet Ginekol Indones 2012; 36-3: 135-9]
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This high mortality rate is mainly caused by the
lack of complain in the main stages of this disease,
leading to a difficulty in making an early diagnosis.
It is estimated that about 75% of ovarium cancer
has already spread outside the ovarium or me-
tastized to distant site when the diagnosis is made,
causing an unsatisfying result and low 5-year sur-
vival rate (± 40%).4,5
The management of ovarium cancer is deciced
based on the stages, differentiation, preservation of
fertility and the general condition of the patient.
The management of late stages ovarium cancer pa-
tient consists of the combination of cytoreductive
operation and chemotherapy. The objective of che-
motherapy is mainly to prevent the multiplication
of cancerous cells, their invasions and metastasis.
The combination of taxane and platinum/paclitaxel
with carboplatin or cisplatin) is one of the chemo-
therapy regiment used for the management of
ovarium cancer.6
A study of GOG 158 compared the effectivity of
carboplatin and paclitaxel combination wth cis-
platin and paclitaxel combination. The result is a
similiar survival rate, but more severe cases of gas-
trointestinal problem and neurotoxicity in the
group receiving cisplatin. Based on these studies,
the recommended chemotherapy combination for
late stage ovarium cancer is the combination of
paclitaxel and carboplatin.6-8
For the last few years, the understanding on the
molecular biology, especially angiogenesis, in ovar-
ium cancer has improved. It brought a new finding
on the target of therapy and a new molecular based
prognostic factor. This caused a development of
more radical treatment on ovarium cancer. Factors
influencing angiogenesis are playing a key role in
understanding the mechanism and management of
ovarium cancer. One of the aforementioned factors
is the vascular endothelial growth factor (VEGF).
VEGF is the main signal, which utilized by the
oxygen-deprived cells to induce the development of
new blood vessels. VEGF is the main regulator of
angiogenesis, performing its action by stimulating
mitogenesis from endothelial cells and increasing
the vascular permeability. VEGF also plays a role in
lymphangiogenesis, which is the development of
new lymphatic vessels. The lymphatic drainage sys-
tem is important in maintaining the fluid balance in
the tissues, mediating afferent immune response
and also in the metastation of malignant tumor to
the regional lymph node.9
Several studies has already insinuated that VEGF-
induced angiogenesis is a major component in the
development of ovarium cancer. The immunostain-
ing of VEGF has shown in the epithelial cells of be-
nign ovarium neoplasma. The microvascular den-
sity and expression of VEGF and its receptor in the
ovarium tumor are associated with poor prognosis,
and this suggest that angiogenesis, possibly through
VEGF, influences the progresivity of the disease.10
Mesiano et al had found the role of VEGF in the
occurrence of ascites fluid in epithelial cell type
ovarium cancer. In the end, they used the human
ovarium cancer cell, SKOV-3, to develop an in vivo
model of ovarium cancer in immunodeficient
mices. The cancer developed into intraperitoneal
cancer and there is also ascites fluid build up com-
monly seen in ovarium cancer patients.11
Some researches examined the level of VEGF in
the tissue of the tumor. The findings from several
studies showed that the level of circulating VEGF
was associated with the progressivity of the dis-
ease, response to chemotherapy and the life expec-
tancy rate. This showed a possible use of examin-
ing the level of VEGF in the blood serum or
plasma.11
The combination of chemotherapy in the ther-
apy of ovarium cancer influences the angiogenic
factor, including VEGF. The general characteristic
of cancer cells is their fast multiplication caused by
angiogenesis mechanism. Platinum-based drugs
will influence the cell cycle in mitotic phase by pre-
venting the multiplication of cells and inducing
apoptosis and the Taxane-based drugs will inter-
fere with DNA synthesis. These mechanisms will
cause the expression of VEGF declined.12
The role of VEGF in the growth and development
of the ovarium cancer is very important. By under-
standing its role on the growth, invasion and the
spread of cancer cells, we could understand more
about the development of ovarium cancer and the
potential of VEGF as a target for therapy. Studies
need to be performed to further evaluate whether
the currently standard regiment of chemotherapy
resulting in decreasing level of VEGF, thus prevent-
ing the growth, invasion and spread of cancer cells.
METHOD
This was a cohort study aimed to evaluate the re-
sponse to Paclitaxel-Carboplatin chemotherapy
combination in epithelial cell ovarium cancer by
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examining the change in the serum level of VEGF.
This study was performed in several hospital ac-
quintanced with Department of Obstetrics and
Gynecologic in Faculty of Medicine Hasanuddin
University, Makassar: Dr. Wahidin Sudirohusodo
Hospital, Pelamonia Hospital, Faisal Hospital, La-
buang Baji General Hospital, and Bhayangkara Ge-
neral Hospital. This study was conducted from 1st
April 2011 to 31st March 2012. The subject of this
study is ovarium cancer patient who had been op-
erated on and given 3 series of Paclitaxel-Car-
boplatin chemotherapy combination. The patients
must never had chemotherapy before, had no other
malignancies such as colon cancer, liver cancer,
lung cancer and breast cancer. The level of serum
VEGF was examined with sandwich enzyme immu-
noassay technique (Immunology assay with quan-
titatively layered enzyme). This study used human
VEGF immunoassay, catalog number DVEoo, R&D
systems product. A VEGF-spesific polyclonal anti-
body was alyered on a microplate. The sample was
taken with a pipette, put into a tube, and the VEGF
would be bound by immobilized antibody. After
being cleaned from unbound compounds, a poly-
clonal antibody bound to an enzyme and specific
for VEGF would also be put into the test tube. After
washing to eliminate unbinding antibody-enzyme
reagent, a substrate would be added into the crook,
making an appearance of color consistent with the
level of VEGF (pro and/or active), which was
bound, in the early steps. The color changing proc-
ess than stopped and the color intensity was meas-
ured in ng/ml.
RESULT
This study was performed on 30 patients, 43.86
years old on average (the age range was 19-55
years old). Sixteen patients were under 45 years
old and 14 cases were over 45 years old. Most pa-
tients were nulliparous. The most common histo-
logical type was adenocarcinoma serosum, found
in 16 cases (46.7%). There were 9 well-differenti-
ated cases (30%), 11 moderately differentiated
cases (36.7%), and 10 poorly differentiated cases
(33.3%). Most cases (73%) were in the advanced
stages. 
Table 1 showed that the mean level of serum
VEGF before chemotherapy was 572.77 (SD±346.21)
and after chemotherapy was 294.67 (SD±144.11).
Statistically, there was a significant difference of
VEGF serum level before and after chemotherapy,
with p value of 0.000 (p<0.05).
Table 1. The comparison of serum VEGF level before and
after Paclitaxel-Carboplatin chemotherapy regiment in epi-
thelial cell type ovarium cancer
n=30 Min Max Mean p*
VEGF(ng/ml)
Before 176.40 1521.70 572.77
0.000
After 85.40 590.30 294.67
*Paired t-test
Table 2 showed that the VEGF serum level in
epithelial cell type ovarium cancer declined signifi-
cantly after chemotherapy, both in the early stage
Table 2. The comparison of serum VEGF level before and after Paclitaxel-Carboplatin chemotherapy regiment in epithelial
cell type ovarium cancer based on the stages
Stages
VEGF (ng/ml)
p*Before chemotherapy After chemotherapy Change
Mean SD Mean SD Mean SD
Early 484.66 272.59 313.95 147.32 170.71 140.95 0.011
Advanced 604.81 369.75 287.65 145.78 317.15 309.10 0.000
*Paired t-test
Table 3. The Comparison of serum VEGF level in epithelial cell type ovarium cancer before and after Paclitaxel-Carboplatin
chemotherapy regiment based on the histologic type
Histologic type
VEGF (ng/ml)
p*Before chemotherapy After chemotherapy Change
Mean SD Mean SD Mean SD
Adenoca mucinosum 447.25 189.21 332.65 141.52 114.59 106.69 0.003
Adenoca serosum 699.98 407.59 271.68 152.73 428.30 301.89 0.000
*Paired t-test
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cases (p-0.011) and the advanced stage cases
(p=0.000). It also showed that the change in VEGF
level was greater in the advanced stage cases.
Table 3 showed that the VEGF serum level in
epithelial cell type ovarium cancer declined signifi-
cantly after chemotherapy, both in the adenocarci-
noma mucinosum (p=0.003) and serosum (p=0.000).
We could see that the change in VEGF level was
greater in adenocarcinoma serosum, which showed
that the adenocarcinoma serosum type gave a
better response to Paclitaxel-Carboplatin chemo-
therapy combination.
DISCUSSION
In this study, most cases were over 45 years old
(53.3%). Theoretically, ovarium cancer is rarely
found in women below 40 years old. The incidence
will rise along with age, from 15 per 100,000 in
women aged 40-44 years old, to 57 per 100,000 in
women aged 70-74 years old. The average age of
the patients by the time of diagnosis was 63 years
old and 48% patients were over 65 years old. The
study performed by Okayasa et al in 2007 found
that women over 45 years old had 2.8 times more
risk to suffer ovarium cancer.6,13
There were 16 patients younger than 45 years
old in this study. This could happen since there is
a lot of predispositing factor of ovarium cancer,
such as hereditary factor, early menarche, the high
rise of infertility treatment, endometriosis, hormo-
nal therapy, and pelvic inflammatory disease,
which occurring more often in women. Those fac-
tors could cause a spontaneous mutation, which in
turn could end up as the development of ovarian
cancer.14
Most patients were nulliparous, which sup-
ported the incessant ovulation hypothesis by
Fathalia (1972) that cellular trauma in the surface
epithelial ovarium during each ovulation, happen-
ing regularly without a break, would cause the epi-
thelial cell to undergo a neoplastic change.14
Epidemiologically, more than half of ovarium
cancer cases are adenocarcinoma m=serosum, and
only 5-10% are adenocarcinoma mucinosum.15 In
this study, most cases are adenocarcinoma sero-
sum (53,3%) and the rest were adenocarcinoma
mucinosum.
The level of serum VEGF after chemotherapy
regiment declined significantly (from 572.77 ng/ml
to 294.67 ng/ml; p=0.000). This indicated that there
was a response towards the chemotherapy based
on the VEGF level. The target of chemotherapy is to
prevent the multiplication, invasion and spread of
the cancer cells. VEGF, an angiogenesis factor re-
sponsible in the process of cancer cells invasion and
spread, turned out to have a good response towards
Paclitaxel-Carboplatin chemotherapy regiment, ex-
cept in adenocarcinoma mucinosum, which will be
explained later. Until recently, there was no study
that examined the correlation of the change in VEGF
level with the prognosis of ovarium cancer.9,15
In this study, the change in VEGF level was
greater in the advanced stage cases compared to
the early stage cases (604.81 ng/ml vs 484.66
ng/ml), eventhough there was still a significant
change before and after chemotherapy in both
stages. This pointed to the fact that angiogenesis
palys a great role in the growth and spread of ovar-
ium cancer, considering that in the advanced stage,
a massive angiogenesis and lymphangiogenesis
had already happened because of the high level of
VEGF. This shows that there is a significant relation
between the activation of VEGF and invasion and
metastasis of ovarium cancer.
VEGF caused angiogenesis, tumor growth and
tissue metastasis due to hypoxia in cancer cells.
The rising level of VEGF found in tumor cells is re-
lated to malignant transformation. Several studies
proved that the expression of VEGF was an inde-
pendently significant predictor for relapse rate and
the overall prognosis.10
The higher responsiveness of cancer in the ad-
vanced stage could be explained by the pattern of
growth known as Gompertz growth. When a cancer
is small in size and the mass is still unpalpable, it
will grow exponentially. In this phase, the cells will
be more sensitive towards chemotherapy because
most cells are in the active phase of the cell cycle.
Thus, the metastazing cells are more sensitive to-
wards the chemotherapy compared with the pri-
mary tumor itself. In other words, late stages ovar-
ium cancer, which has already metastasized, will
be more sensitive towards chemotherapy.16
In this study, the VEGF serum level in epithelial
cell type ovarium cancer declined significantly after
chemotherapy, both in the adenocarcinoma muci-
nosum (p=0.003) and serosum (p=0.000). We could
see that the change in VEGF level was greater in
adenocarcinoma serosum (428.30 ng/ml) compared
to adenocarcinoma mucinosum (114.59 ng/ml).
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A genetic and molecular study shows a differ-
ence between adenocarcinoma mucinosum and se-
rosum, which support the concept that these two
types of tumor are separated in the development.
Several studies showed that adenocarcinoma muci-
nosum had a differen pattern of molecular expres-
sion with other type of cancer such as serosum and
endometrioid. Several other studies also showed
that a mutation on RAS (especially KRAS on codon
12) is oftern found in the adenocarcinoma mucino-
sum, but not in other types. On contrary, a muta-
tion on P53 gene, which associated with the sensi-
tivity towards Paclitaxel, is rarely found in adeno-
carcinoma mucinosum. Besides, the experession of
COX-2 is also rarely found in adenocarcinoma
mucinosum, but more often in adenocarcinoma se-
rosum.17
 The histological difference of the type of ovarian
cancer is still under research, considering the rela-
tively poor response of adenocarcinoma mucino-
sum towards both single or combination chemo-
therapy. Adenocarcinoma mucinosum also has a
poorer life expectancy rate, making it a priority to
determine a chemotherapy regiment specifically
designed for it.17,18
Clinically, a grading system is important on the
management of cancer, because it could influence
the prognosis and recurrency rate. Higher grade
mostly means that the mitotic process on the can-
cer is alos greater, thus making it more responsive
towards chemotherapy. In this study all degree of
differentiation showed a significant response to-
wards the chemotherapy regiment. But it could be
observed that the well or moderate differentiated
cancer gave better response compared to the poor
differentiated. But this also influenced by the his-
tological type and stage of the cancer when the che-
motherapy was performed.17,18
CONCLUSION
There was a significant difference of VEGF serum
level before and after Paclitaxel-Carboplatin che-
motherapy regiment, in all stages, histologic type
and level of differentiation of ovarium cancer.
 REFERENCES
1. The National Comprehensive Cancer Network and the
American Cancer Society: Ovarian cancer treatment guide-
lines for patients. 2007. Version III.
2. Ovarian Cancer National Alliance: Statistics. Washington
D.C. (Online). Available from: (http://www.ovariancancer.org/
about-ovarian-cancer/statistics).
3. Santin AD. Role of Immunohistochemical Expression of
HER2/neu in High-grade Ovarian Serous Papillary Cancer;
in Handbook of Immunohistochemistry and In Situ Hybridi-
zation of Human Carcinomas. Elsevier Academic Press, Lon-
don. 2006; 333-8.
4. Paley PJ. Screening for The Major Malignancies Affecting
Women. Current Guide Obstet Gynecol. 2001;184:1021-30.
5. Colombo N, Gorp VT, Parma G, et al. Ovarian Cancer. Euro-
pean Institute of Oncology, Division of Gynecology, Italy
University Hospitals Leuven, Milan. 2006: 159-79.
6. Busmar B. Kanker Ovarium; in Aziz MF, Andrijono, Saifud-
din AB, Buku Acuan Nasional Onkologi. Edisi pertama.
Yayasan Bina Pustaka Sarwono Prawirodihardjo, Jakarta.
2006: 468-527.
7. See HT, Kavanagh J, Hu W, Bast RC. Targeted Therapy for
Epithelial Ovarian Cancer, Current status and Future Pros-
pects. Department of Gynecological Medical Oncology and
experimental therapeutics, University of Texas, Anderson
Cancer Center. Houston, Texas. 2003; 702-15.
8. Ozols RF. Treatment Goals in Ovarian Cancer. Division of
Medical Science, Fox Chase Cancer Center. Philadelphia,
Pennsylvania. 2005: 5.
9. Mesiano S, Ferrara. Role of Vascular Endothelial Growth
Factor in Ovarian Cancer. Am J Pathol. 1998; 153:1249-56.
10. Bamberger ES. Angiogenesis in Epithelial Ovarian Cancer. J
Clin Pathol. 2002; 55: 348-59.
11. Tortora G, Ciardiello F. Angiogenesis: A Target for Cancer
Therapy. Current Pharmaceutical Design. 2004; 10:11-26.
12. Fitzpatrick FA, Wheeler R. The Immunopharmacology of
Paclitaxel (TaxolR), Docetaxel (TaxotereR), and Related
Agents. Departments of Oncological Science and Medicinal
Chemistry. Huntsman Cancer Institute, University of Utah,
Salt Lake City. 2003:1699-1714.
13. Kramer JL, Greene MH. Epidemiology of Ovarian, Fallopian
Tube and Primary Peritoneal Cancers. in Controversy in
Management on Gynecologic Cancers. Philadelphia: Elsevier
Churchill Livingstone. 2004; 327-40.
14. Morgan RJ, Alvarez RD, Amstrong DK, et al. Ovarian Cancer.
National Comprehensive Cancer Network, Clinical Practice
Guidelines in Oncology. 2006; version 1.
15. Scorge JO. Principles of Chemotherapy; in Williams Gyne-
cology. The McGraw Hill companies, inc. United Stated.
2008: 586-600.
16. Hamilton S. Chemotherapy Drugs, (Online) Available from:
(http://www.chemocare.com/bio/carboplatin.asp).
17. Pisano C, Greggi S, Tambaro R. Activity of Chemotherapy in
Mucinous Epithelial Ovarian Cancer: A Retrospective Study.
Anticancer Research. 2005; 25:3501-6.
18. Kaku T, Ogawa S, Kawano Y. Histological classification of
Ovarian Cancer. Med Electron Microsc. 2003; 36:9-17.
Vol 36, No 3
July 2012 VEGF serum on epithelial ovarian cancer  139
|
